GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » Current Ratio

AVITA Medical (AVITA Medical) Current Ratio : 7.88 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. AVITA Medical's current ratio for the quarter that ended in Dec. 2023 was 7.88.

AVITA Medical has a current ratio of 7.88. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for AVITA Medical's Current Ratio or its related term are showing as below:

RCEL' s Current Ratio Range Over the Past 10 Years
Min: 2.86   Med: 5.56   Max: 16.42
Current: 7.88

During the past 13 years, AVITA Medical's highest Current Ratio was 16.42. The lowest was 2.86. And the median was 5.56.

RCEL's Current Ratio is ranked better than
85.93% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: 2.74 vs RCEL: 7.88

AVITA Medical Current Ratio Historical Data

The historical data trend for AVITA Medical's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Current Ratio Chart

AVITA Medical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.38 10.17 16.42 8.18 7.88

AVITA Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.18 7.21 5.61 6.25 7.88

Competitive Comparison of AVITA Medical's Current Ratio

For the Medical Devices subindustry, AVITA Medical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Current Ratio distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Current Ratio falls into.



AVITA Medical Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

AVITA Medical's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=104.006/13.199
=7.88

AVITA Medical's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=104.006/13.199
=7.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVITA Medical  (NAS:RCEL) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


AVITA Medical Current Ratio Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVITA Medical (AVITA Medical) Business Description

Address
28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Executives
James Corbett director 2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
David D O'toole officer: CFO 1640 MARENGO STREET, LOS ANGELES CA 90033
Donna Shiroma officer: General Counsel C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance director 800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
Michael S Perry director, officer: Chief Executive Officer C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Suzanne Crowe director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Jan Stern Reed director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder officer: Chief Financial Officer 6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee officer: Chief Operating Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins officer: Sr. VP of Finance C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre officer: Chief Financial Officer SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Damien Mcdonald director 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Erin Liberto officer: Chief Commercial Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355